Search Results 1061-1070 of 15943 for Residual

1. A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma - Mayo Clinic

   Patients must have recovered from adverse events due to prior anti-cancer therapy (i.e., may not have residual toxicities > grade 1 or above baseline), ...

2. A Study to Optimize Endocrine Therapy Through Motivational Interviewing and Text Interventions - Mayo Clinic

   Women who have undergone neo-adjuvant chemotherapy who have no residual invasive disease post-surgery are eligible based on an initial pathologically confirmed ...

3. Gastroenterology and Hepatology - Clinical trials

   [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

4. Breast radiotherapy team at Mayo Clinic adopts shortened courses to spare normal tissue

   A clinical trial investigating the combination of radiotherapy plus an ATR inhibitor for patients with residual triple-negative or high-risk hormone ...

5. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   All visible tumor must be completely resected 60 days prior to registration (residual pure CIS is permitted). All patients must have histologically ...

6. Non Hodgkin Clinical Trials - Mayo Clinic Research

   ... residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of ...

7. Conventionally Fractionated Vs. Hypofractionated Comprehensive Nodal Irradiation For Breast Cancer Using Pencil Beam Scanning ProtonTherapy - Mayo Clinic

   Residual gross disease detected by imaging or clinical exam with the exception of <2cm internal mammary lymph node or supraclavicular lymph node amenable to ...

8. Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone - Mayo Clinic

   ... residual detection. Measurable disease is defined as one or more of the following: serum M protein > 0.5 G/DL;; urine M protein >200 MG/24H;; serum FLC assay ...

9. Study Of Datopotamab Deruxtecan Plus Carboplatin Or Cisplatin Versus Gemcitabine Plus Carboplatin Or Cisplatin In Participants With Locally Advanced Or Metastatic Urothelial Carcinoma - Mayo Clinic

   Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies which may include: Hypothyroidism/ hyperthyroidism. Type I ...

10. Mayo Clinic Laboratories.